Gary James Connett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7808155/publications.pdf

Version: 2024-02-01

103 papers	5,483 citations	172207 29 h-index	82410 72 g-index
105 all docs	105 docs citations	105 times ranked	6645 citing authors

#	Article	IF	Citations
1	The Asthma Epidemic. New England Journal of Medicine, 2006, 355, 2226-2235.	13.9	1,432
2	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, The, 2019, 394, 1940-1948.	6.3	804
3	British Guideline on the Management of Asthma. Thorax, 2008, 63, iv1-iv121.	2.7	655
4	Difficult/therapyâ€resistant asthmaThe need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. European Respiratory Journal, 1999, 13, 1198.	3.1	313
5	Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Molecular Therapy, 2017, 25, 2104-2116.	3.7	149
6	Prevention of viral induced asthma attacks using inhaled budesonide.. Archives of Disease in Childhood, 1993, 68, 85-87.	1.0	135
7	Use of 16S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2006, 44, 2601-2604.	1.8	129
8	Pseudomonas aeruginosainfection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Review of Respiratory Medicine, 2016, 10, 685-697.	1.0	114
9	Cystic Fibrosis Diagnosed After 2 Months of Age Leads to Worse Outcomes and Requires More Therapy. Pediatrics, 2007, 119, 19-28.	1.0	110
10	Use of budesonide in severe asthmatics aged 1-3 years.. Archives of Disease in Childhood, 1993, 69, 351-355.	1.0	89
11	Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis. FEMS Microbiology Letters, 2017, 364, .	0.7	85
12	Airway Microbiome and Development of Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review. Journal of Pediatrics, 2019, 204, 126-133.e2.	0.9	81
13	Prednisolone and salbutamol in the hospital treatment of acute asthma.. Archives of Disease in Childhood, 1994, 70, 170-173.	1.0	55
14	Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches. BMC Pulmonary Medicine, 2009, 9, 14.	0.8	55
15	Molecular Microbiological Characterization of Preterm Neonates at Risk of Bronchopulmonary Dysplasia. Pediatric Research, 2010, 67, 412-418.	1.1	55
16	A Population-Based Study of Fish Allergy in the Philippines, Singapore and Thailand. International Archives of Allergy and Immunology, 2012, 159, 384-390.	0.9	54
17	A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital. Archives of Disease in Childhood, 1999, 80, 421-423.	1.0	52
18	Review article: enzyme supplementation in cystic fibrosis, chronic pancreatitis, pancreatic and periampullary cancer. Alimentary Pharmacology and Therapeutics, 2010, 32, 1-25.	1.9	52

#	Article	IF	Citations
19	Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 22-28.	0.3	50
20	Interferon alpha Âtreatment of molluscum contagiosum in immunodeficiency. Archives of Disease in Childhood, 1999, 80, 77-79.	1.0	43
21	Dietary fibre and the occurrence of gut symptoms in cystic fibrosis. Archives of Disease in Childhood, 1997, 76, 35-37.	1.0	42
22	Inhaled budesonide and behavioural disturbances. Lancet, The, 1991, 338, 634-635.	6.3	40
23	Use of pulse oximetry in the hospital management of acute asthma in childhood. Pediatric Pulmonology, 1993, 15, 345-349.	1.0	36
24	Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal, 2013, 7, 204-213.	0.6	36
25	Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy . Drug Design, Development and Therapy, 2019, Volume 13, 2405-2412.	2.0	35
26	Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 117-125.	1.3	35
27	Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis. Redox Biology, 2020, 32, 101436.	3.9	35
28	Dysfunctional Breathing in Children and Adults With Asthma. Frontiers in Pediatrics, 2018, 6, 406.	0.9	34
29	Psychometric evaluation of a patient-reported outcome measure in pancreatic exocrine insufficiency (PEI). Pancreatology, 2019, 19, 182-190.	0.5	32
30	Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome (PRO) Instrument. Patient, 2017, 10, 615-628.	1.1	31
31	Faecal Elastase 1: A Marker of Exocrine Pancreatic Insufficiency in Cystic Fibrosis. Annals of Clinical Biochemistry, 1999, 36, 739-742.	0.8	30
32	Bronchoalveolar lavage. Paediatric Respiratory Reviews, 2000, 1, 52-56.	1.2	30
33	Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. European Journal of Pediatrics, 1996, 155, 706-711.	1.3	29
34	Bronchoscopic appearances of congenital lobar emphysema. , 1996, 21, 195-197.		29
35	Lung resection in cystic fibrosis patients with localised pulmonary disease.. Archives of Disease in Childhood, 1996, 74, 449-451.	1.0	28
36	Lung function reference values in Singaporean children aged 6-18 years.. Thorax, 1994, 49, 901-905.	2.7	27

#	Article	IF	Citations
37	Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of Vİ‡<scp>o</scp>_{2max} in people with cystic fibrosis: a retrospective analysis. Journal of Applied Physiology, 2018, 125, 1277-1283.	1.2	27
38	Cephalosporin-3â€²-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae Biofilms. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	26
39	Resolution of peanut allergy following bone marrow transplantation for primary immunodeficiency. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 536-537.	2.7	25
40	The use of culture-independent tools to characterize bacteria in endo-tracheal aspirates from pre-term infants at risk of bronchopulmonary dysplasia. Journal of Perinatal Medicine, 2010, 38, 333-7.	0.6	22
41	Colonic wall thickening is related to age and not dose of high strength pancreatin microspheres in children with cystic fibrosis. European Journal of Gastroenterology and Hepatology, 1999, 11, 181-184.	0.8	21
42	Acute intestinal obstruction as a presentation of cystic fibrosis in infancy. Journal of Cystic Fibrosis, 2008, 7, 277-279.	0.3	21
43	Audit strategies to reduce hospital admissions for acute asthma.. Archives of Disease in Childhood, 1993, 69, 202-205.	1.0	20
44	Prolonged hypoxaemia after nebulised salbutamol.. Thorax, 1993, 48, 574-575.	2.7	20
45	Treating childhood asthma in Singapore: when West meets East. BMJ: British Medical Journal, 1994, 308, 1282-1284.	2.4	17
46	Juvenile Laryngeal Papillomatosis. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 125-127.	2.5	16
47	A Quantitative Analysis of Ureaplasma urealyticum and Ureaplasma parvum Compared with Host Immune Response in Preterm Neonates at Risk of Developing Bronchopulmonary Dysplasia. Journal of Clinical Microbiology, 2012, 50, 909-914.	1.8	16
48	A rare cause of upper airway obstruction in a 5-year-old girl: a laryngeal web. Paediatric Anaesthesia, 2003, 13, 722-724.	0.6	15
49	Maldigestion and malabsorption of 13C labelled tripalmitin in gastrostomy-fed patients with cystic fibrosis. Clinical Nutrition, 2004, 23, 347-353.	2.3	15
50	The prevalence of stress urinary incontinence in patients with cystic fibrosis: an under-recognized problem. Journal of Pediatric Urology, 2005, 1, 5-9.	0.6	15
51	Long term results of lung resection in cystic fibrosis patients with localised lung disease. Archives of Disease in Childhood, 2002, 86, 66-66.	1.0	11
52	A 2-year post-authorization safety study of high-strength pancreatic enzyme replacement therapy (pancreatin 40,000) in cystic fibrosis. Expert Opinion on Drug Safety, 2011, 10, 197-203.	1.0	11
53	Ready, Steady, Go â€“ Achieving successful transition in cystic fibrosis. Paediatric Respiratory Reviews, 2018, 27, 13-15.	1.2	11
54	Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials. Thorax, 2022, 77, 873-881.	2.7	11

#	Article	IF	Citations
55	G385 RATNO - Reducing Antibiotic Tolerance using Nitric Oxide in Cystic Fibrosis: report of a proof of concept clinical trial. Archives of Disease in Childhood, 2014, 99, A159-A159.	1.0	10
56	Inflammatory pseudotumor of the trachea in a ten-month-old infant. , 1997, 23, 307-309.		9
57	Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis. Pediatric Pulmonology, 2003, 35, 463-466.	1.0	9
58	Colloidal silver for lung disease in cystic fibrosis. Journal of the Royal Society of Medicine, 2008, 101, 51-52.	1.1	8
59	The implications of dysglycaemia on aerobic exercise and ventilatory function in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 427-433.	0.3	8
60	Flexible fibre-optic bronchoscopy in the management of lung complications in cystic fibrosis. Acta Paediatrica, International Journal of Paediatrics, 1996, 85, 675-678.	0.7	7
61	Nutritional outcomes in cystic fibrosis â€“ are we doing enough?. Paediatric Respiratory Reviews, 2015, 16, 31-34.	1.2	7
62	A public health emergency among young people. Lancet Respiratory Medicine,the, 2020, 8, 231-233.	5.2	6
63	Falsely elevated serum tobraycin levels in a patient receiving nebulised tobramycin. Journal of Cystic Fibrosis, 2002, 1, 146-147.	0.3	5
64	Routine use of daily oral vitamin K to treat infants with cystic fibrosis. Paediatric Respiratory Reviews, 2015, 16, 22-24.	1.2	5
65	Diagnosis of cystic fibrosis : Indian perspective. Indian Journal of Pediatrics, 1999, 66, 923-928.	0.3	4
66	Contributions of Composition and Interactions to Bacterial Respiration Are Reliant on the Phylogenetic Similarity of the Measured Community. Microbial Ecology, 2017, 74, 757-760.	1.4	4
67	Effects of an acaricide on asthmatic children with house dust mite allergy. Pediatrics International, 1994, 36, 669-672.	0.2	3
68	Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study. Therapeutic Advances in Respiratory Disease, 2015, 9, 272-280.	1.0	3
69	The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis. Paediatric Respiratory Reviews, 2018, 27, 16-17.	1.2	3
70	Evaluation of the impact of shielding to avoid COVID-19 infection on respiratory symptoms in children with severe asthma. Archives of Disease in Childhood, 2021, 106, e23-e23.	1.0	3
71	Veno-venous haemodiafiltration in meningococcal septicaemia. Lancet, The, 1996, 347, 611-614.	6.3	2
72	Primary Tracheomalacia and Persistent Wheezing in Cystic Fibrosis During Infancy. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 161-163.	0.8	2

#	Article	IF	Citations
73	Children must be protected from the tobacco industry's marketing tactics. BMJ, The, 2013, 347, f7358-f7358.	3.0	2
74	Evaluation of a regionally based preceptorship programme for newly qualified neonatal nurses. Journal of Neonatal Nursing, 2018, 24, 225-228.	0.3	2
75	Determining the reasons for poorly controlled asthma in an adolescent. BMJ: British Medical Journal, 2019, 364, l75.	2.4	2
76	The ERS approach to e-cigarettes is entirely rational. European Respiratory Journal, 2020, 55, 2000413.	3.1	2
77	The impact of plasma 25â€hydroxyvitamin D on pulmonary function and exercise physiology in cystic fibrosis: A multicentre retrospective study. Journal of Human Nutrition and Dietetics, 2021, , .	1.3	2
78	Lung resection for the treatment of severe localised bronchiectasis in cystic fibrosis patients. Acta Chirurgica Hungarica, 1999, 38, 23-5.	0.0	2
79	Acute wheezy bronchitis–lumping and splitting.. Archives of Disease in Childhood, 1991, 66, 751-752.	1.0	1
80	Day care and asthma morbidity. Journal of Paediatrics and Child Health, 1994, 30, 257-259.	0.4	1
81	rhDNase in cystic fibrosis. Thorax, 1999, 54, 750-750.	2.7	1
82	Pancreatic enzymes and fibrosing colonopathy. Lancet, The, 1999, 354, 249.	6.3	1
83	Cystic Fibrosis Nutrition â€“ Chewing the Fat. Paediatric Respiratory Reviews, 2016, 17, 42-44.	1.2	1
84	Meconium Ileus due to GUCY2C gene mutations in three unrelated South Indian families. Journal of Cystic Fibrosis, 2021, 20, e84-e86.	0.3	1
85	Diffuse Microcystic Pancreatic Enlargement in a Cystic Fibrosis Patient Causing Severe Gastrointestinal Symptoms and Successfully Treated by Total Pancreatectomy. Journal of Pediatric Gastroenterology and Nutrition, 1998, 26, 454-457.	0.9	1
86	Individualised field testing is a useful tool to evaluate difficult asthma. , 2017, , .		1
87	Lung function and nutritional status in children with cystic fibrosis and primary ciliary dyskinesia. , 2016, , .		1
88	Structured transition is associated with improved outcomes in diabetes. Practical Diabetes, 2022, 39, 18.	0.1	1
89	Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. European Journal of Pediatrics, 1996, 155, 706-711.	1.3	1
90	Pancreatic enzymes and fibrosing colonopathy. Lancet, The, 1999, 354, 249-250.	6.3	0

#	Article	IF	Citations
91	Editorial. Indian Journal of Pediatrics, 2000, 67, 121-122.	0.3	0
92	Somatizing disorders affecting the respiratory tract. Indian Journal of Pediatrics, 2000, 67, 129-131.	0.3	0
93	Idiopathic Bilateral Vocal Cord Palsy in Extremely Premature Neonates. Journal of Bronchology, 2006, 13, 221-222.	0.2	0
94	Chest x ray and high-resolution computed tomography in cystic fibrosis. Archives of Disease in Childhood, 2006, 91, 1043-1043.	1.0	0
95	Manifesting carriage of a Duchenne muscular dystrophy mutation: an unusual cause of impaired lung function in CF. Journal of the Royal Society of Medicine, 2010, 103, 27-29.	1.1	0
96	166 Improvements in inhalational treatment amongst children using the Philips I-neb insight online software. Journal of Cystic Fibrosis, 2015, 14, S100.	0.3	0
97	P415 Medicine possession ratios for ivacaftor prescriptions data in children and adults with cystic fibrosis attending a UK regional centre. Journal of Cystic Fibrosis, 2019, 18, S174-S175.	0.3	0
98	P209 Use of lumacaftor/ivacaftor as rescue therapy and stabilisation treatment for severe lung disease in children with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, S116.	0.3	0
99	Reply to Askew and Green. Journal of Applied Physiology, 2019, 126, 512-512.	1.2	0
100	Reply to Cooper. Journal of Applied Physiology, 2019, 126, 265-265.	1.2	0
101	The impact of plasma 25-hydroxyvitamin d on lung function in patients with cystic fibrosis. Clinical Nutrition ESPEN, 2020, 40, 537-538.	0.5	0
102	Primary ciliary dyskinesia exhibits dysregulated epithelial responses to non-typeable Haemophilus influenzae. , 2017, , .		0
103	Central and obstructive apnoea-hypopnea indices pre and post growth hormone commencement in children with Prader-Willis syndrome following introduction of a screening programme. , 2020, , .		0